Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Eli Lilly Q2 2024 Earnings Highlights: Exceptional Growth Driven by New Products

by Team Lumida
August 10, 2024
in Equities
Reading Time: 9 mins read
A A
0
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Eli Lilly delivered exceptional Q2 2024 results, with revenue growth of 36% driven by strong performance of new products, particularly Mounjaro and Zepbound.

Top Takeaways

  1. Revenue grew 36% in Q2, with new products contributing nearly $3.5 billion in growth compared to the same period last year.
  2. Mounjaro and Zepbound sales exceeded expectations, with combined U.S. sales of $3.6 billion in Q2.
  3. Lilly raised full-year revenue guidance by $3 billion, reflecting strong performance and increased confidence in production expansion.
  4. The company received FDA approval for Kisunla (donanemab) for Alzheimer’s disease treatment.
  5. Lilly is investing heavily in manufacturing expansion, committing over $18 billion since 2020 to build, upgrade, or acquire facilities in the U.S. and Europe.

Summary

Eli Lilly’s Q2 2024 performance was marked by accelerated growth, with revenue increasing 36% to $45.4-$46.6 billion. The company’s new products, particularly Mounjaro and Zepbound, drove this exceptional growth. CEO Dave Ricks highlighted the company’s progress:

“It’s an exciting time here at Lilly as our growth trajectory accelerated in the second quarter. Our investments in advancing innovative medicine are focused on manufacturing expansion are bringing Lilly medicines to more people around the world.”

Main Themes

  • Guidance: Full-year revenue outlook raised by $3 billion to $45.4-$46.6 billion
  • New Product Announcements: FDA approval of Kisunla for Alzheimer’s disease treatment
  • Manufacturing Expansion: $18 billion committed since 2020 for facility upgrades and acquisitions
  • Pipeline Progress: Positive Phase 3 results for tirzepatide in heart failure and obesity
  • Market Opportunity: Expanding presence in obesity and diabetes markets globally

Insights

Lilly’s strategy in the obesity market is comprehensive, addressing multiple mechanisms, indications, and dosage forms. The company now has 11 new molecules in clinical trials across various indications, demonstrating its commitment to this growing market segment.

Market Opportunity

Lilly is targeting the global obesity market, which represents a significant growth opportunity. The company is expanding its presence in international markets, with Mounjaro launches progressing well in countries like the UK, Germany, and UAE. The addressable market for obesity treatments is expanding as more employers opt into coverage for these medications.

Market Commentary

The obesity treatment market is experiencing rapid growth and increased competition. Lilly is positioning itself as a leader in this space through its comprehensive approach to drug development and manufacturing expansion. The company’s focus on multiple mechanisms and formulations (oral and injectable) aims to address various patient needs and preferences.

Customer Behaviors

Patient demand for Mounjaro and Zepbound remains strong and growing. Lilly is working to improve patient persistence with therapy by enhancing consumer platforms and digital channels. The company is also engaging with employers to communicate the broader health and productivity benefits of obesity treatments.

Capex

Lilly announced an additional $5.3 billion investment in its Lebanon, Indiana manufacturing site, bringing the total investment there to $9 billion. This expansion will enhance capacity to manufacture active pharmaceutical ingredients for Zepbound and Mounjaro.

Regulatory Policy

Lilly received FDA approval for Kisunla (donanemab) for Alzheimer’s disease treatment. The approval includes labeling that allows physicians to consider stopping dosing based on reduction of amyloid plaques, potentially leading to lower treatment costs and fewer infusions required.

Economy Insights

While specific economic commentary was limited, Lilly’s strong performance and increased guidance suggest resilient demand for its products despite broader economic uncertainties.

Industry Insights

Lilly’s success in the obesity and diabetes markets may have positive implications for other players in the pharmaceutical industry focused on these therapeutic areas. The company’s manufacturing expansion efforts highlight the importance of robust supply chains in meeting growing demand for innovative treatments.

Key Metrics

Financial Metrics

  • Revenue growth: 36% YoY
  • U.S. revenue growth: 42% YoY
  • Operating income increase: 90% YoY
  • Earnings per share: $3.92, up 86% YoY

KPIs

  • Mounjaro global sales: $3.1 billion
  • Zepbound U.S. sales: Over $1.2 billion
  • Verzenio sales growth: 44% YoY
  • Commercial access for Zepbound: 86% as of July 1

Competitive Differentiators

  1. Comprehensive obesity treatment portfolio with 11 molecules in clinical trials
  2. Strong manufacturing capabilities and ongoing expansion efforts
  3. Multiple formulations (oral and injectable) addressing various patient needs
  4. Robust pipeline across multiple therapeutic areas
  5. Successful launch and rapid uptake of new products like Mounjaro and Zepbound

Key Risks

  1. Potential supply constraints due to high demand for incretin medicines
  2. Increasing competition in the obesity and diabetes markets
  3. Regulatory challenges and potential pricing pressures
  4. Dependence on key products for growth
  5. Manufacturing and supply chain complexities

Analyst Q&A Focus Areas

Analysts focused on:

  1. Pricing dynamics and average selling prices for incretin medicines
  2. Manufacturing capacity and supply chain challenges
  3. Differentiation strategies for oral obesity treatments
  4. Ex-U.S. market opportunities and reimbursement landscape
  5. Potential for muscle-preserving obesity drugs

Eli Lilly Summary:

Eli Lilly’s exceptional Q2 2024 performance demonstrates the company’s strong position in the rapidly growing obesity and diabetes markets. With significant investments in manufacturing capacity, a robust pipeline, and successful new product launches, Lilly is well-positioned for continued growth. Investors should watch for further developments in the company’s obesity treatment portfolio, international market expansions, and progress in addressing supply chain challenges to meet the growing demand for its innovative medicines.

Tags: EARNINGSEliLilly
Previous Post

Bumble Inc. Q2 2024 Earnings Highlights: Strategic Reset Amid Growth Challenges

Next Post

Cheniere Energy Q2 2024 Earnings Highlights: Exceeding Expectations and Raising Guidance

Recommended For You

JPMorgan Names Bregje de Best as Its Next CFO, With Jeremy Barnum Moving to Vice Chairman and Staying Through Early 2028

by Team Lumida
7 hours ago
Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

JPMorgan plans to name Bregje de Best CFO after first-quarter results, with Jeremy Barnum becoming vice chairman through early 2028.

Read more

‘Big Short’ Investor Steve Eisman Says AI Neoclouds Are in ‘Big Trouble’ as Nvidia’s ‘Virtual Vertical Holding Company’ Unwinds

by Team Lumida
8 hours ago

Steve Eisman said AI neocloud stocks face the biggest fallout from the Nvidia scandal and favored hyperscalers if data center building slows.

Read more

Jensen Huang Will Testify Before Three House Committees on Dec. 1, as Nvidia Creates a Board Committee to Oversee Export Controls and National Security

by Team Lumida
8 hours ago

Former Nvidia CEO Jensen Huang will appear before three House panels Dec. 1 as Nvidia formed a board committee on export controls.

Read more

Options Price a 7% Nvidia Earnings Move, the Biggest Since February 2025, as the Stock Sits 35% Below Its October High and Morgan Stanley Calls It the Most Under-Owned Large-Cap Tech Name

by Team Lumida
8 hours ago

Options traders priced a 7% Nvidia earnings move, the biggest since early 2025, with shares down 35% from their October high and widely under-owned.

Read more

Nike Reaffirms Fiscal 2027 Guidance and Targets $3.00-$3.50 EPS and 12%-14% Margins by 2031 at Its First Investor Day in Nine Years

by Team Lumida
8 hours ago

Nike reaffirmed its fiscal 2027 outlook and set 2031 targets of $3.00 to $3.50 adjusted EPS and 12% to 14% operating margins at its investor day.

Read more

Disney Beats With $1.77 Adjusted EPS on $25.95 Billion Revenue, Targets $3 Billion of Savings by 2029 and Lifts Its Dividend 33% to $2

by Team Lumida
8 hours ago

Disney beat fiscal Q4 estimates, targeted $3 billion in cost savings by fiscal 2029 and raised its annual dividend 33% to $2 a share.

Read more

Home Depot Names CFO Richard McPhail CEO as Ted Decker Steps Down, While Q3 Comps Rise 2.2% but a Soft Holiday Outlook Sends Shares Lower

by Team Lumida
8 hours ago

Home Depot named CFO Richard McPhail CEO and beat Q3 estimates, but a cautious full-year outlook implied fourth-quarter EPS below consensus.

Read more

Anthropic Is Likely to Price Its IPO Above the $70-$78 Range as Books Close, With Nasdaq Trading Under ‘ANT’ Set for Nov. 19

by Team Lumida
8 hours ago

Anthropic is likely to price its IPO above the $70 to $78 range, sources told CNBC, ahead of its Nasdaq debut under the ticker ANT on Nov. 19.

Read more

Aschenbrenner’s Situational Awareness Rebuilt an AI Book Led by a $440 Million SharonAI Stake Before an October Rout That Cut SharonAI 58% and IREN 41%

by Team Lumida
16 hours ago

Situational Awareness’ 13F shows a renewed AI-heavy book, including SharonAI, Cleanspark, IREN and options on Nebius and Sandisk, before a sharp October selloff.

Read more

Berkshire Adds 7.13 Million Delta Shares, Lifting Its Stake 12% to $5.37 Billion, While Selling More Than $1.6 Billion of Bank of America

by Team Lumida
16 hours ago

Berkshire’s 13F shows a 12% bigger Delta stake, a roughly 6% Bank of America trim, a new Bending Spoons stake and a near-doubled Lennar holding.

Read more
Next Post

Cheniere Energy Q2 2024 Earnings Highlights: Exceeding Expectations and Raising Guidance

Datadog Q2 2024 Earnings Highlights: Solid Performance Driven by Enterprise Growth

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

turned on monitoring screen

Bond Rout Deepens: 30-Year Treasury Yields Hit 19-Year High as Wall Street Sees No End in Sight

August 19, 2026
blue and red cargo ship on sea during daytime

Hormuz Deal Unravels — Ship Struck Off Oman as Talks Bog Down Over Fees, Oil Prices Reverse Higher

August 4, 2026
Why Iran Thinks It Won the War — Despite Catastrophic Military Losses

Why Iran Thinks It Won the War — Despite Catastrophic Military Losses

April 9, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018